Skip to content

What Now, What Next? Appropriate management for mUC
Tweetorial #2: Second- and Subsequent-line Therapy
*Activity Post-Survey & Application for Credit*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.68yo female with metastatic urothelial carcinoma (mUC)
  • Status post treatment with enfortumab vedotin and pembrolizumab
  • On pembrolizumab monotherapy for 12 months
  • FGFR3 and cisplatin eligible
  • Presents with new liver metastases
In your practice, what would you use next?(Required.)
4.74yo female status post treatment with gem/ + cisplatin
  • Avelumab maintenance x12m
  • 🧬No FGFR3 alterations, HER2 IHC 0
  • Presents with new liver mets
What treatment should you use next? (Required.)
5.67 year old male patient with mUC status post treatment with EV+P
  • FGFR3 alteration
  • Treated with erdafitinib in the second-line
  • Serum phosphate 8.0 mg/dL
What should you do next?(Required.)
EVALUATION FORM
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Describe efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC.
7.Please indicate the extent of your agreement with the following statements: 
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
8.Overall, was this activity fair, balanced and free from commercial bias?
9.If no, please explain:
10.What percentage of activity content was new to you?
11.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
12.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
13.Based on your experience, which of the following are the primary PATIENT-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):
14.Based on your experience, which of the following are the primary PROVIDER-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):
15.Based on your experience, which of the following are the primary SYSTEM-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):
16.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
17.I certify that I have participated in the continuing education activity entitled, "Tweetorial #2: Second- & Subsequent-line Therapy in mUC" and claim 0.25 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice